The case for & against
Bull & Bear analysis
Bearish
iSpecimen Inc. (NASDAQ: ISPC) is a specialized player in the biotechnology sector, focusing on providing human biospecimens and associated data, primarily serving healthcare researchers and life sciences organizations. The company operates a tech-driven marketplace that connects suppliers with researchers, ensuring efficient access to critical samples needed for advancing biomedical research. In light of ongoing operational and market challenges, iSpecimen has emphasized enhancing its operational efficiencies and expanding its supplier relationships to adapt to shifting demands in cancer and genomic research.
Bull says
- ↑Q2 2024 revenue $2.9M, up 76% YoY
- ↑Specimen count rose 26% to 5,918 in Q2
- ↑Next Day Quotes conversion climbed to 58%
- ↑Cash burn cut to $2.9M in H1 2024 (–59%)
- ↑Tech investment $5.39M in 2023 to boost platform
- ↑G&A expenses down 40% to $1.1M in Q2
Bear says
- ↓FY2023 revenue fell 4.5% to $9.93M
- ↓Specimen count declined 11% to 24,565 in FY2023
- ↓Negative earnings yield and weak profitability factors
- ↓Cash position dropped to $5.01M by end-2023
- ↓High short interest signals bearish sentiment
- ↓Low growth outlook and elevated leverage risk
Earnings Call · Q2 2023 · Mgmt. Guidance
Updated 06-29-2026neutral
Transcript signals
Bull points
- Despite the fact that we recognize record levels of opportunities in quotes, we experienced lower than expected conversions of quotes to purchase orders in Q1, which in turn left us with a much lower backlog of purchase orders at the beginning and early portion of Q2 compared to prior quarters.
- I'm also pleased to report that our active collection efforts in Q2 were successful in reversing the downward receivable payment trend that we experienced in Q1.
- Thus far in Q3, and despite a continued industry-wide slowdown, our business has greatly improved as evidenced by stronger sales and backlog, both of which have returned to more historical levels.
Bear points
- our second quarter results came in below expectations.
- The decrease in revenue was discussed earlier and was attributable to a decrease of 2,322 specimens or 33% in specimen account from 7,004 specimens in the three months into June 30 of 2022 to 4,682 specimens in the three months into June 30 of 2023.
- The decrease in revenue for the six-month period ended June 30th, 2023, was attributable to a decrease in average selling price per specimen of $64, or 16%, from approximately $407 in the six months into June 30th, 2022, to $343 in the six months into June 30th, 2023.
Read full transcript analysis ›